Genmab A/S (NASDAQ:GMAB) Reaches New 12-Month Low – What’s Next?

Genmab A/S (NASDAQ:GMAB) shares reached a new 52-week low during mid-day trading on Monday . The stock traded as low as $18.87 and last traded at $18.99, with a volume of 103803 shares. The stock had previously closed at $19.00.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on GMAB shares. BMO Capital Markets restated an “outperform” rating and set a $48.00 target price (up from $46.00) on shares of Genmab A/S in a report on Friday, November 8th. HC Wainwright reissued a “buy” rating and issued a $50.00 price objective on shares of Genmab A/S in a research note on Thursday, January 23rd. Finally, Sanford C. Bernstein upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Friday, December 20th. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, Genmab A/S currently has an average rating of “Moderate Buy” and a consensus target price of $45.20.

Genmab A/S Trading Up 1.1 %

The firm has a market cap of $12.50 billion, a PE ratio of 18.34, a PEG ratio of 0.54 and a beta of 0.96. The firm has a 50 day moving average price of $20.78 and a 200-day moving average price of $23.30.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. boosted its position in shares of Genmab A/S by 94.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 26,104 shares of the company’s stock worth $636,000 after acquiring an additional 12,654 shares in the last quarter. HighTower Advisors LLC purchased a new stake in Genmab A/S during the third quarter worth approximately $273,000. Verition Fund Management LLC acquired a new position in Genmab A/S in the third quarter valued at approximately $709,000. FMR LLC increased its stake in Genmab A/S by 13.5% in the third quarter. FMR LLC now owns 278,194 shares of the company’s stock valued at $6,782,000 after purchasing an additional 33,076 shares during the last quarter. Finally, Natixis Advisors LLC increased its stake in Genmab A/S by 29.8% in the third quarter. Natixis Advisors LLC now owns 206,563 shares of the company’s stock valued at $5,036,000 after purchasing an additional 47,437 shares during the last quarter. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.